通过单细胞 RNA 测序和体外实验整合研究三种乳腺癌亚型中异质性肿瘤相关巨噬细胞的作用机制。
Study on the mechanism of heterogeneous tumor-associated macrophages in three subtypes of breast cancer through the integration of single-cell RNA sequencing and in vitro experiments.
机构信息
Center for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
Department of Basic Clinical Laboratory Medicine, School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, 550004, China.
出版信息
Mol Biol Rep. 2024 Jun 1;51(1):720. doi: 10.1007/s11033-024-09665-5.
BACKGROUND
Tumor-associated macrophages (TAM) exert a significant influence on the progression and heterogeneity of various subtypes of breast cancer (BRCA). However, the roles of heterogeneous TAM within BRCA subtypes remain unclear. Therefore, this study sought to elucidate the role of TAM across the following three BRCA subtypes: triple-negative breast cancer, luminal, and HER2.
MATERIALS AND METHODS
This investigation aimed to delineate the variations in marker genes, drug sensitivity, and cellular communication among TAM across the three BRCA subtypes. We identified specific ligand-receptor (L-R) pairs and downstream mechanisms regulated by VEGFA-VEGFR1, SPP1-CD44, and SPP1-ITGB1 L-R pairs. Experimental verification of these pairs was conducted by co-culturing macrophages with three subtypes of BRCA cells.
RESULTS
Our findings reveal the heterogeneity of macrophages within the three BRCA subtypes, evidenced by variations in marker gene expression, composition, and functional characteristics. Notably, heterogeneous TAM were found to promote invasive migration and epithelial-mesenchymal transition (EMT) in MDA-MB-231, MCF-7, and SKBR3 cells, activating NF-κB pathway via P38 MAPK, TGF-β1, and AKT, respectively, through distinct VEGFA-VEGFR1, SPP1-CD44, and SPP1-ITGB1 L-R pairs. Inhibition of these specific L-R pairs effectively reversed EMT, migration, and invasion of each cancer cells. Furthermore, we observed a correlation between ligand gene expression and TAM sensitivity to anticancer drugs, suggesting a potential strategy for optimizing personalized treatment guidance.
CONCLUSION
Our study highlights the capacity of heterogeneous TAM to modulate biological functions via distinct pathways mediated by specific L-R pairs within diverse BRCA subtypes. This study might provide insights into precision immunotherapy of different subtypes of BRCA.
背景
肿瘤相关巨噬细胞(TAM)对各种亚型乳腺癌(BRCA)的进展和异质性有显著影响。然而,BRCA 各亚型内异质性 TAM 的作用尚不清楚。因此,本研究旨在阐明 TAM 在以下三种 BRCA 亚型中的作用:三阴性乳腺癌、管腔型和 HER2 型。
材料和方法
本研究旨在描绘三种 BRCA 亚型中 TAM 的标记基因、药物敏感性和细胞通讯的变化。我们鉴定了特定的配体-受体(L-R)对以及由 VEGFA-VEGFR1、SPP1-CD44 和 SPP1-ITGB1 L-R 对调节的下游机制。通过将巨噬细胞与三种 BRCA 细胞共培养来验证这些配对。
结果
我们的研究结果揭示了三种 BRCA 亚型中巨噬细胞的异质性,表现在标记基因表达、组成和功能特征的变化。值得注意的是,发现异质性 TAM 促进 MDA-MB-231、MCF-7 和 SKBR3 细胞的侵袭性迁移和上皮间质转化(EMT),分别通过 P38 MAPK、TGF-β1 和 AKT 激活 NF-κB 通路,通过不同的 VEGFA-VEGFR1、SPP1-CD44 和 SPP1-ITGB1 L-R 对。抑制这些特定的 L-R 对可有效逆转每种癌细胞的 EMT、迁移和侵袭。此外,我们观察到配体基因表达与 TAM 对抗癌药物敏感性之间存在相关性,这表明了优化个性化治疗指导的潜在策略。
结论
我们的研究强调了异质性 TAM 通过特定的 L-R 对在不同 BRCA 亚型中介导的不同途径调节生物学功能的能力。这项研究可能为不同 BRCA 亚型的精准免疫治疗提供思路。